Up to 20% of pharma brands moving digital media spend to point-of-care
Two point-of-care companies have received hundreds of millions of dollars in funding. One of them, Outcome Health, is facing allegations about padding data.
Most recent articles by Jaimy Lee
Five things for pharma marketers to know: Thursday, October 19, 2017
The FDA approves Kite’s CAR-T therapy; Omnicom reports strong Q3 performance for healthcare agencies; Hearst to acquire Rodale, up health presence
Five things for pharma marketers to know: Wednesday, October 18, 2017
More than half of doctors say patients make critical, racist, or sexist comments; Anthem to launch its own PBM; drugmakers face criticism for waste
Five things for pharma marketers to know: Tuesday, October 17, 2017
J&J reports 15% lift in pharma sales in Q3; Apple reportedly considers buying medical clinics; survey finds need for digital investment in payer marketing
Five things for pharma marketers to know: Thursday, October 12, 2017
Merck scraps plans for cholesterol drug; oncologist describes how he tells people about his work; researchers question list of side effects in DTC ads
Five things for pharma marketers to know: Wednesday, October 11, 2017
Pfizer considers sale of its consumer healthcare business; Express Scripts moves into patient benefit management; China to speed up drug approvals
Five things for pharma marketers to know: Tuesday, October 10, 2017
Patients complain about positive healthcare ads; some drugmakers skirt Open Payment rules; new law requires disclosure of drug price hikes in California
Five things for pharma marketers to know: Friday, October 6, 2017
AbbVie to pay $140 million to AndroGel patient; Trump likely to roll back birth-control mandate; patients more likely to respond to expensive drugs
Five things for pharma marketers to know: Thursday, October 5, 2017
Cigna will no longer cover OxyContin; the AMA no longer supports price-fixing to lower drug prices; Gottlieb is not in favor of ‘right-to-try’ laws
Five things for pharma marketers to know: Thursday, September 28, 2017
Universities stock vending machines with women’s health products; AbbVie pays to delay Amgen’s Humira biosimilar; more states likely to introduce off-label bills
